loading
Schlusskurs vom Vortag:
$52.60
Offen:
$52.91
24-Stunden-Volumen:
2.09M
Relative Volume:
0.75
Marktkapitalisierung:
$9.79B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-21.25
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-4.07%
1M Leistung:
+4.32%
6M Leistung:
+57.13%
1J Leistung:
+90.02%
1-Tages-Spanne:
Value
$51.03
$54.29
1-Wochen-Bereich:
Value
$51.03
$54.60
52-Wochen-Spanne:
Value
$21.72
$54.60

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Firmenname
Bridgebio Pharma Inc
Name
Telefon
(650) 391-9740
Name
Adresse
3160 PORTER DR., PALO ALTO, CA
Name
Mitarbeiter
730
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BBIO
Bridgebio Pharma Inc
51.21 10.12B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
394.53 99.62B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
465.89 61.52B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.00 58.91B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
756.38 46.69B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
324.34 34.54B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-30 Fortgesetzt Raymond James Outperform
2025-07-21 Eingeleitet Truist Buy
2025-07-14 Eingeleitet Jefferies Buy
2025-07-09 Hochstufung Oppenheimer Perform → Outperform
2025-06-17 Eingeleitet Wolfe Research Outperform
2025-03-31 Eingeleitet Redburn Atlantic Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-03 Eingeleitet Oppenheimer Perform
2024-09-04 Eingeleitet Piper Sandler Overweight
2024-03-21 Fortgesetzt Raymond James Outperform
2024-01-31 Eingeleitet BMO Capital Markets Market Perform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-07 Eingeleitet Citigroup Buy
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-07-18 Herabstufung Jefferies Buy → Hold
2023-04-19 Eingeleitet Evercore ISI Outperform
2023-02-06 Eingeleitet Cowen Outperform
2021-12-27 Bestätigt Mizuho Buy
2021-12-27 Bestätigt SVB Leerink Outperform
2021-09-10 Hochstufung BofA Securities Neutral → Buy
2021-05-21 Eingeleitet UBS Buy
2021-03-22 Bestätigt Goldman Buy
2021-02-22 Fortgesetzt JP Morgan Overweight
2021-02-09 Fortgesetzt Goldman Buy
2021-01-11 Bestätigt H.C. Wainwright Buy
2020-12-10 Bestätigt H.C. Wainwright Buy
2020-06-25 Eingeleitet BofA/Merrill Neutral
2020-05-19 Eingeleitet BTIG Research Buy
2020-04-13 Eingeleitet H.C. Wainwright Buy
2020-02-19 Eingeleitet Mizuho Buy
2019-07-26 Eingeleitet Raymond James Outperform
2019-07-22 Eingeleitet BMO Capital Markets Outperform
2019-07-22 Eingeleitet Goldman Buy
2019-07-22 Eingeleitet JP Morgan Overweight
2019-07-22 Eingeleitet Jefferies Buy
2019-07-22 Eingeleitet Piper Jaffray Overweight
2019-07-22 Eingeleitet SVB Leerink Outperform
Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

pulisher
08:55 AM

Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN

08:55 AM
pulisher
Sep 12, 2025

BridgeBio Pharma stock price target raised to $82 from $72 at UBS - Investing.com Canada

Sep 12, 2025
pulisher
Sep 12, 2025

BBIO Stock: UBS Raises Price Target Amidst Continued Buy Rating | BBIO Stock News - GuruFocus

Sep 12, 2025
pulisher
Sep 12, 2025

BridgeBio (BBIO) Challenges Pfizer's ATTR-CM Promotion Tactics - GuruFocus

Sep 12, 2025
pulisher
Sep 12, 2025

Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha

Sep 12, 2025
pulisher
Sep 12, 2025

Fred Alger Management LLC Invests $982,000 in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 12, 2025
pulisher
Sep 11, 2025

Alliancebernstein L.P. Has $92.79 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

UBS Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

Sep 11, 2025
pulisher
Sep 11, 2025

Baird Financial Group Inc. Acquires Shares of 41,326 BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Adage Capital Partners GP L.L.C. Purchases 246,555 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Philosophy Capital Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com

Sep 11, 2025
pulisher
Sep 11, 2025

BridgeBio stock maintains Buy rating at UBS ahead of key trial data - Investing.com Canada

Sep 11, 2025
pulisher
Sep 11, 2025

A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $58 to $76 - 富途牛牛

Sep 11, 2025
pulisher
Sep 11, 2025

BridgeBio Pharma, Inc. $BBIO Shares Sold by Woodline Partners LP - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Zimmer Partners LP Buys 121,000 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Bosun Asset Management LLC Takes $412,000 Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

BridgeBio Pharma, Inc. $BBIO Shares Sold by Exome Asset Management LLC - MarketBeat

Sep 11, 2025
pulisher
Sep 10, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 10, 2025
pulisher
Sep 10, 2025

Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential - TipRanks

Sep 10, 2025
pulisher
Sep 10, 2025

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat

Sep 10, 2025
pulisher
Sep 10, 2025

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $3,933,840.00 in Stock - MarketBeat

Sep 10, 2025
pulisher
Sep 10, 2025

238,168 Shares: BridgeBio Pharma's Major Employee Stock Grants Signal Growth Push in Genetic Disease Research - Stock Titan

Sep 10, 2025
pulisher
Sep 10, 2025

BridgeBio Pharma stock maintains Buy rating at Jefferies on encaleret potential - Investing.com Canada

Sep 10, 2025
pulisher
Sep 10, 2025

Transcript : BridgeBio Pharma, Inc.Special Call - MarketScreener

Sep 10, 2025
pulisher
Sep 09, 2025

Cutter Capital Management LP Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN

Sep 09, 2025
pulisher
Sep 09, 2025

Cormorant Asset Management LP Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock By Investing.com - Investing.com South Africa

Sep 08, 2025
pulisher
Sep 08, 2025

Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock - Investing.com

Sep 08, 2025
pulisher
Sep 08, 2025

Will BridgeBio Pharma Inc. benefit from government policyPortfolio Risk Report & High Conviction Trade Alerts - classian.co.kr

Sep 08, 2025
pulisher
Sep 08, 2025

Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $68 - 富途牛牛

Sep 08, 2025
pulisher
Sep 08, 2025

BridgeBio Pharma Inc. Price Holds Above Key Fib Level2025 Year in Review & Risk Adjusted Swing Trade Ideas - beatles.ru

Sep 08, 2025
pulisher
Sep 08, 2025

BridgeBio’s Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial - Endpoints News

Sep 08, 2025
pulisher
Sep 08, 2025

BridgeBio Pharma (BBIO): Assessing Valuation After Strong Encaleret Data and Pipeline Advances - Yahoo Finance

Sep 08, 2025
pulisher
Sep 08, 2025

TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛

Sep 08, 2025
pulisher
Sep 08, 2025

BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact - TipRanks

Sep 08, 2025
pulisher
Sep 08, 2025

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $70.00 - MarketBeat

Sep 08, 2025
pulisher
Sep 06, 2025

BridgeBio’s encaleret shows promise in hypoparathyroidism treatment By Investing.com - Investing.com Nigeria

Sep 06, 2025
pulisher
Sep 06, 2025

BridgeBio’s encaleret shows promise in hypoparathyroidism treatment - Investing.com India

Sep 06, 2025
pulisher
Sep 06, 2025

BridgeBio Pharma Inc. recovery potential after sell offJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

BridgeBio Pharma Reports Promising Phase 2 Results for Encaleret in Post-Surgical Hypoparathyroidism, Plans Registrational Study for 2026 - Quiver Quantitative

Sep 06, 2025
pulisher
Sep 06, 2025

Encaleret Showed Parathyroid Hormone-Independent - GlobeNewswire

Sep 06, 2025
pulisher
Sep 06, 2025

BridgeBio Pharma says intends to initiate registrational clinical study of Encaleret in 2026 - MarketScreener

Sep 06, 2025
pulisher
Sep 06, 2025

80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study - Stock Titan

Sep 06, 2025
pulisher
Sep 06, 2025

Chart based analysis of BridgeBio Pharma Inc. trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Why is BridgeBio Pharma Inc. stock going down2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک

Sep 06, 2025
pulisher
Sep 06, 2025

HBK Investments L P Invests $519,000 in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Sep 06, 2025
pulisher
Sep 06, 2025

Is BridgeBio Pharma Inc. stock a top performer YTDAnalyst Downgrade & Real-Time Market Trend Scan - خودرو بانک

Sep 06, 2025
pulisher
Sep 05, 2025

BridgeBio Pharma stock hits 52-week high at $52.85 By Investing.com - Investing.com Canada

Sep 05, 2025
pulisher
Sep 05, 2025

BridgeBio Pharma, Inc. $BBIO Shares Acquired by Panagora Asset Management Inc. - MarketBeat

Sep 05, 2025

Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MCCORMICK FRANK
Director
Sep 05 '25
Sale
53.16
74,000
3,933,544
83,275
Kumar Neil
Chief Executive Officer
Sep 05 '25
Sale
53.05
40,000
2,122,047
875,686
Kumar Neil
Chief Executive Officer
Sep 04 '25
Sale
51.34
40,000
2,053,788
895,686
$36.36
price down icon 0.93%
$83.10
price down icon 3.56%
$27.82
price down icon 2.76%
$96.74
price down icon 7.26%
$145.93
price up icon 0.10%
biotechnology ONC
$324.34
price down icon 3.38%
Kapitalisierung:     |  Volumen (24h):